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maceuticals, researchers and diagnostic companies can 
 better focus their biomarker research and development on 
meeting these specific requirements, which should lead to 
the more rapid introduction of new molecular oncology 
tests for patient benefit.  © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 The four most common cancer sites in Europe are 
breast, colorectal, prostate and lung cancers which com-
prise approximately 1.7 million cancers diagnosed or 
about half the incidence of cancer  [1] . Many cancer ther-
apeutics have been or are being developed in these malig-
nancies and their subtypes. The European Medicines 
Agency (EMA) has approved 48 drugs since 1995 which 
address indications in one or more of these cancer dis-
eases; however, only 18 of these therapies are correlated 
with companion diagnostics (CDxs), based on the use of 
5 biomarkers  [2] . Currently, the traditional ‘one size fits 
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 Abstract 
 While personalised cancer medicine holds great promise, 
targeting therapies to the biological characteristics of pa-
tients is limited by the number of validated biomarkers cur-
rently available. The implementation of biomarkers has un-
dergone many challenges with few biomarkers reaching 
cancer patients in the clinic. There have been many biomark-
ers that have been published and claimed to be therapeuti-
cally useful, but few become part of the clinical decision-
making process due to technical, validation and market ac-
cess issues. To reduce this attrition rate, there is a significant 
need for policy makers and reimbursement agencies to de-
fine specific evidence requirements for the introduction of 
biomarkers into clinical practice. Once these requirements 
are more clearly defined, in an analogous manner to phar-
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all’ development of cancer agents leads only to statisti-
cally significant but marginal clinical benefit; so, employ-
ing biomarkers to better select patients for therapies un-
derpins the personalised or precision medicine approach 
to identify reliably those patients who will derive benefit 
from treatment. In 2014, there were approximately 800 
cancer agents in phase II or III clinical trials in the United 
States  [3] ; many of these drugs are intended to target spe-
cific biological pathways; validated biomarkers are re-
quired to identify those tumours in which these drugs are 
likely to be active. Therefore, there is an urgent need to 
develop a system which is more efficient in introducing 
biomarkers into clinical practice. Currently, there are less 
than 20 prognostic or predictive biomarkers which are 
recognised in the 2014 European Society of Medical
Oncology (ESMO) clinical practice guidelines for lung, 
breast, colon and prostate as having sufficient evidence to 
be recommended for clinical practice  [4–8] . In prostate 
cancer, there are a number of prognostic biomarkers 
available to guide clinical management of disease, but 
there are no established predictive biomarkers to choose 
one particular treatment. There have been thousands of 
studies published in the scientific literature claiming can-
cer biomarkers are clinically useful, but these biomarkers 
hardly ever reach clinical application for a wide variety of 
reasons  [9] . Most of the issues relate to analytical and clin-
ical validation, demonstration of clinical utility, regula-
tory approval, health technology assessment, reimburse-
ment and adoption in clinical practice  [10] .
 Valuing Biomarkers or Molecular Diagnostics on a 
Par with Therapeutics 
 Imatinib mesylate is often cited as the first targeted 
therapy, approved in 2001, as it was effective for patients 
with chronic myelogenous leukaemia who were selected 
for treatment based on the presence of a cytogenetic bio-
marker. Patients who responded to this therapy had an 
acquired genetic aberration in their tumour cells known 
as the Philadelphia chromosome and/or the BCR-ABL 
gene  [11] . This targeted therapy and biomarker combina-
tion improved survival in patients with this disease. In an 
analysis of >3,000 patients diagnosed with chronic mye-
logenous leukaemia in the Swedish Cancer Registry be-
tween January 1, 1973, and December 31, 2008, survival 
increased significantly after 2001 for patients up to 79 
years of age  [12] . Overall, 5-year relative survival rates 
were 0.21 in the calendar periods 1973 to 1979 compared 
to 0.80 for patients between 2001 and 2008. The value of 
imatinib mesylate was understood when it was combined 
with a biomarker which identified which patients would 
benefit from this therapeutic intervention.
 As personalised medicine is in its infancy, one of the 
current challenges with the initial class of CDxs is that 
they were developed to predict response to a particular 
drug in low-frequency populations, which is unlikely to 
lead to a cost-effective strategy if many patients need to 
be tested to identify those likely to benefit. An example of 
this is crizotinib, which is an effective treatment for
patients with an ALK aberration in metastatic non-small 
cell lung cancer (NSCLC). If EML4-ALK fusion testing 
was performed on all stage IV non-squamous NSCLC
patients, <5% of the population would be identified for 
crizotinib treatment  [13] . Therefore, in this scenario, one 
would have to order 20 tests to identify 1 patient who may 
benefit from the therapy; so, from the perspective of the 
healthcare system, they have to pay for 20 tests and 1 
course of therapy to find the 1 patient with ALK aberra-
tion who may benefit from crizotinib  [14, 15] .
 Therefore, an emerging option may be to consider mo-
lecular diagnostics in a different way – rather than focus-
sing on a one-to-one relationship between biomarkers 
and therapeutic intervention, consider the development 
of biomarker panels or platforms which would inform 
decisions on multiple drugs and treatment options. Using 
this approach would then permit the development of ro-
bust algorithms to support clinical decision making. This 
platform type approach would allow the value associated 
with testing to be attributed to a wider range of treatment 
options and an increase in the number of validated bio-
markers on the panel would increase the value of the pan-
el  [16] . This concept is similar to Metcalfe’s law, which is 
often used to describe the value of the Internet or social 
media, where an increase in the number of users increas-
es the value of the service to the overall community. 
Therefore, these initial tests should be considered like the 
first Internet users where the costs are higher and the val-
ue will only be realised once the number of validated bio-
markers expands and can be tested on a common plat-
form. While the tests may be able to run on a common 
platform, there will still be cost to validate each biomark-
er independently with each drug for each patient popula-
tion. Ultimately, supporting access to value-based mo-
lecular diagnostics will lead to more investment in new 
biomarkers designed to increase the effectiveness of can-
cer drugs. The initial application of a biomarker platform 
in clinical practice is most relevant in NSCLC, as seen in 
 table 1 , since there are the most approved targeted thera-
pies for these tumours.
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 What Is the Ideal Biomarker? 
 The ideal biomarker is one that supports clinical deci-
sions by defining a particular biological characteristic of 
a particular patient. For example, an ideal predictive bio-
marker for a therapeutic intervention would be binary 
test which would identify 100% of the candidates who will 
respond to the therapy and none of the non-responders 
with appropriate levels of sensitivity and specificity. 
Comprehensive evidence would have been generated for 
analytical, clinical validity, clinical utility and cost-effec-
tiveness of this biomarker, allowing the patient, physician 
and healthcare system to use the biomarker-drug combi-
nation with a high level of confidence. This degree of 
rigour allows all stakeholders to be confident that (a) the 
test is relevant to address the specific clinical question and 
(b) the test will be performed accurately, precisely and 
reproducibly and that the strength of the correlation be-
tween biomarker and use of the drug is high.
 Thus far, we have considered biomarkers in the con-
text of identifying which patients will respond to a par-
ticular therapy. Additional biomarkers may also be rele-
vant for assessing toxicity, deciding dosing schedule or 
measuring response to therapy. For example, the current 
gold standard for assessing a patient’s response to ima-
tinib mesylate involves the use of a real-time quantitative 
PCR assay that measures BCR-ABL transcripts (a BCR 
ABL/ABL ratio). A three-log reduction in BCR-ABL/ABL 
ration within a specific time after therapy equates with a 
molecular response to imatinib mesylate treatment. Oth-
er biomarkers that may be relevant include those which 
assess risk/benefits of particular treatment options. In all 
of these scenarios, appropriate clinical research should 
inform the evidence for the application of a biomarker in 
a particular clinical setting.
 Validation of Molecular Diagnostics or Biomarkers 
 Many high-quality guidelines have been published 
which clearly outline the standards required for validat-
ing biomarkers  [17–25] . The gold standard for predictive 
biomarkers still relies on randomised controlled clinical 
trials. However, validating biomarkers in prospective 
randomised controlled clinical trials is becoming increas-
ingly costly, especially as many emerging biomarkers are 
addressing small populations and studies need to recruit 
patients from multiple countries to identify a sufficient 
number of patients to report meaningful results. Apply-
ing approaches from rare cancers could be considered to 
a broader set of clinical research where direct randomised 
trial evidence is considered with a higher level of uncer-
tainty around the results  [26] . There is a need to have
researchers, regulators and reimbursement agencies to 
align on clinical trial methodologies that can be used to 
validate biomarkers knowing that randomised controlled 
clinical trials are not always feasible. For example, using 
archival tissue from randomised controlled clinical trials 
or large registry cohorts can provide relevant informa-
tion. This approach is being employed by the Stratifica-
tion in COloRecTal Cancer (S-CORT) consortium to de-
velop and validate new biomarkers in over 2,000 archival 
patient samples from clinically well-annotated ran-
domised clinical trials and cohort studies  [27] .
 Key Principles in the Validation of Molecular 
Diagnostics 
 Most biomarkers can be classified as providing either 
prognostic or predictive information. A prognostic mark-
er is measured before treatment to indicate the outcome 
for patients that are untreated (pure prognostic marker) 
or receive a standard treatment (context-specific prog-
nostic marker). A predictive marker is measured before 
treatment to identify patients who will or will not benefit 
from a particular therapy. ‘A biomarker is predictive if the 
treatment effect (experimental compared with control) is 
 Table 1.  Currently available CDxs in breast, colorectal, lung and 
prostate cancers
Year Therapeutic
area
Medicine
name
Common
name
CDx
1996 breast Fareston toremifene ER
1996 lung Hycamtin topotecan EGFR
2000 breast Herceptin trastuzumab HER2+
2000 breast Arimidex anastrozole ER
2001 breast Femara letrozole ER
2004 colorectal Erbitux cetuximab RAS WT
2004 breast Faslodex fulvestrant ER
2005 lung Tarceva erlotinib EGFR
2005 breast Aromasin exemestane ER
2007 colorectal Vectibix panitumumab RAS WT
2008 breast Tyverb lapatinib HER2+
2009 breast Afinitor everolimus HR+,
HER2-neg
2009 lung Iressa gefitinib EGFR
2012 lung Xalkori crizotinib ALK
2013 lung Giotrif afatinib EGFR
2013 breast Kadcyla trastuzumab
emtansine
HER2+
2013 breast Perjeta pertuzumab HER2+
2015 lung Zykadia ceritinib ALK
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different for biomarker-positive patients compared with 
biomarker-negative patients’, and a ‘formal test for an in-
teraction between the biomarker and treatment group is 
shown to have a significant interaction’  [28] . In certain 
cases, prognostic markers may wrongly be considered to 
have also a predictive value, especially when they can 
identify patients who have a very good prognosis, irre-
spective of therapy. This biomarker, even if it is not strict-
ly speaking ‘predictive’, still provides valuable informa-
tion on the likely benefit of that particular therapy in this 
low-risk group. An example of this is for stage 2 colon 
cancer patients who are DNA mismatch repair (MMR) 
deficient; as their prognosis is very good, they are unlike-
ly to benefit from fluorouracil + leucovorin chemothera-
py. On the other hand, it would be inappropriate to attri-
bute to this marker a predictive value as a decision made 
based on MMR status to limit therapeutic intervention in 
a higher-risk group would lead to undertreatment. There-
fore, it is important to consider both the prognostic and 
predictive information together to understand overall 
outcome before considering the benefit of a particular 
therapy.
 Relevance of Population for Validation and ‘Intended 
Use of the Biomarker’ 
 When a molecular diagnostic test is developed, it is 
important that there is a clear intended use for the bio-
marker in a specific group of patients. One of the chal-
lenges with many biomarkers is that even if they provide 
prognostic or predictive information which are consis-
tently and independently validated (clinical validity), this 
information is not actionable because the markers are 
not therapeutically relevant (clinical utility). For exam-
ple, if you have a test that identifies patients who are like-
ly to recur 6 months earlier than that indicated by cur-
rently available methods, but none of the currently avail-
able therapies will change the patient’s outcome, the 
information that the biomarker provides does not offer 
any actionable information for clinicians. Another key 
issue is the appropriate definition of the patient group for 
which the biomarker is intended to be used. For example, 
if one develops a test to identify a group of early-stage 
cancer patients who are unlikely to benefit from a spe-
cific therapy, but the test is validated in a group of pa-
tients with very low risk of recurrence based on tradi-
tional parameters, it is unlikely that the test will offer 
much value. This is why biomarkers should be validated 
in patients with similar characteristics to the patients for 
which the biomarker is intended for use in the clinical 
setting.
 Analytical Validation 
 Before any molecular diagnostic is validated to dem-
onstrate its clinical value, it is first important that the as-
say methods are validated which includes the pre-analyt-
ical and the post-analytical steps. Analytical validation is 
an important first step to confirm that the methods used 
for the molecular diagnostic is accurate, precise, repro-
ducible, specific and robust in all the settings where the 
assay may be conducted. Many biomarkers used in clini-
cal practice today have a discordance rate of 10–15% be-
tween local and central testing, and there are many rea-
sons for this, including how the specimen is prepared, 
differences in test protocols and methods, cut-off points 
and method of reporting  [29] . In many countries, the cur-
rent regulatory requirements are designed to support 
quality systems and reproducibility of the diagnostic  [30] .
 Clinical Validity 
 Clinical validity is defined as the ability for a biomark-
er to accurately and reliably predict the clinically defined 
disorder or phenotype of interest  [31] . It is essential that 
the methodology used for validation appropriately as-
sesses the clinical value of the assay as an independent 
factor in addressing the clinical question that the bio-
marker is intended to address. One of the biggest chal-
lenges in validating biomarkers is that there are many 
sources of bias that can impact a specific result. There-
fore, repeated validation in multiple studies with consis-
tent results is a prerequisite before an assay is introduced 
into clinical practice. Examples of a molecular diagnostics 
which followed this approach were KRAS and Oncotype 
DX breast cancer assay.
 Besides validating a biomarker in a randomised con-
trolled clinical trial, there are other methodologies which 
can provide a high level of evidence if conducted in a ro-
bust manner based on archived tissue. One of the first 
examples where this approach was followed by regulatory 
agencies involved the approval of cetuximab and panitu-
mumab for use in metastatic colorectal cancer patients 
with wild-type KRAS tumours by the EMA; this decision 
was made based on KRAS mutational data generated 
from 4 randomised pivotal trials (2 cetuximab, 2 panitu-
mumab)  [32] . The guidelines generated by EMA are in-
creasingly being followed by clinicians, guideline com-
mittees and reimbursement agencies to support the use of 
KRAS testing in this setting. A second example is the On-
cotype DX breast cancer assay which was developed in 
2003. The assay was defined specifically and was analyti-
cally validated before its first clinical validation study was 
conducted  [33] . Following this step, the assay was vali-
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dated in 9 additional studies that were based on archival 
tissue, the majority of which came from randomised con-
trolled studies  [34] . The first results from the TAILORx 
study, a study which prospectively assigned patients to 
chemotherapy based on the Oncotype DX score, has re-
cently been published. This study has reported that 99.3% 
of the patients with low Oncotype DX assay recurrence 
scores between 0 and 10, treated with endocrine therapy 
alone, were free of distant recurrence at 5 years  [35] . 
These results are consistent with those results from stud-
ies using a prospective retrospective design. Simon et al. 
[18] proposed four main criteria, listed in  table  2 , that 
should be considered for a prospective retrospective de-
sign to have a high level of evidence.
 Utilising Population-Based Cohorts to Validate 
Markers with High Level of Evidence 
 While prospective studies based on archived tissue 
from randomised controlled clinical trials are increasing-
ly useful to validate biomarkers, there are not randomised 
clinical trials with archived samples to address every 
question that biomarkers can help answer. Therefore, 
there will be a need to develop methodologies and guide-
lines to use large population-based cohorts to validate 
biomarkers with a high level of evidence, especially for 
early-stage disease where long follow-up is needed to 
demonstrate clinical utility. For example, new prostate 
cancer genomic tests have been introduced which are de-
veloped to identify patients who are candidates for active 
surveillance based on prostate cancer biopsy, and it is un-
likely that archived biopsy tissue samples are available 
from well-conducted large prospective clinical trials that 
randomised patients between active surveillance and ac-
tive treatment (radiation or prostatectomy)  [36] . Several 
commercially available multiple gene panels such as Pro-
laris, Oncotype DX Genomic Prostate Score and Deci-
pher have recently become available to estimate disease 
outcome in different clinical settings that have been vali-
dated in population-based studies. These gene panels are 
currently employed in clinical practice to help decide for 
active surveillance or treatment with curative intent. Due 
to the lack of randomised controlled clinical trials with 
archived tissue, the current assays have been validated 
retrospectively in large population-based cohorts follow-
ing validation principles such as having pre-specified 
protocol and statistical plan.
 Clinical Utility 
 Clinical utility is used to define whether a biomarker 
will impact treatment decisions and will lead to an im-
provement in patient outcomes  [24, 37] . The Evaluation 
of Genomic Applications in Practice and Prevention 
(EGAPP) defines the clinical utility of a genetic test as the 
evidence of improved measurable clinical outcomes and 
its usefulness and added value to patient management
decision-making compared with current management 
without genetic testing  [31] . Patient outcomes can be im-
proved through a decision to either receive a treatment 
which improves the patient’s prognosis, or by avoiding an 
unnecessary treatment that can impact the patient’s qual-
ity of life. A biomarker can be considered useful if the re-
sults are actionable and lead to a better treatment ap-
proach. Clinical utility can often be demonstrated in 
studies that show that a molecular diagnostic test will 
modify a treatment approach based on the results of the 
test. If practice patterns are significantly different in dif-
ferent markets, it is important to establish clinical utility 
according to local practice. For this reason, some reim-
bursement and health technology agencies are focused on 
understanding clinical utility in a real world setting as 
clinical decisions are multifactorial, and the impact of a 
test can be most appropriately evaluated relative to other 
factors. In general, there are disparate assessment ap-
proaches regarding the definition and demonstration of 
clinical utility by different stakeholders in different 
healthcare systems, so more uniform standards for evi-
dence requirements are needed especially as clinical prac-
tice patterns are heterogeneous across countries.
 Economic Validation 
 Cost-effectiveness is used to define whether a specific 
technology represents good value for money. Cost-effec-
tiveness analyses therefore compare the costs and out-
comes of therapeutic alternatives. While economic evalu-
 Table 2. Validation using archived specimens in evaluation of 
prognostic and predictive biomarkers
1 There should be sufficient representative samples from the 
original randomised controlled clinical trial to ensure 
adequate statistical power
2 The test should be analytically and pre-analytically validated 
for use with archived tissue
3 There should be a pre-specified protocol and statistical plan 
for the biomarker evaluation
4 The results from the study should be confirmed in an 
independent study using archived specimens with a 
consistent approach 
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ations of molecular diagnostics are similar to those for 
therapeutics, there is a need to integrate particular pa-
rameters that are specific to diagnostics  [38] . The first pa-
rameter to capture is the imperfection of the diagnostic 
test. This usually corresponds to the specificity and sen-
sitivity of the diagnostic test with particular focus on the 
positive and negative predictive values. The second pa-
rameter that needs to be incorporated into the economic 
analysis is the clinical utility of the diagnostic test (impact 
of the test on treatment decision making). Molecular di-
agnostics also provide value to physicians and patients as 
they increase certainty in treatment decisions. This so 
called ‘value of knowing’ is more difficult to quantify and 
is therefore not often incorporated into the cost-effective-
ness analyses.
 If cost-effectiveness informs policy makers on whether 
molecular diagnostics represent good value for money 
and are therefore worth funding, it does not address af-
fordability questions. This is why budget impact analysis 
is also normally required by budget holders. Budget im-
pact analyses focus on short-term costs and savings. 
Knowing that healthcare budgets are limited, the objective 
of budget impact analyses is to inform budget allocation.
 While many healthcare systems tend to focus more 
heavily on budget impact, cost-effectiveness is the first 
important question to be addressed. Both analyses should 
therefore be considered to inform reimbursement and 
funding decisions. Specific attention must be given to the 
budget silo issue – it is not uncommon for savings to oc-
cur in one budget but for the innovation to be paid for 
from another. This can lead to situations where the chance 
of new molecular diagnostic reaching patients becomes 
even less likely. Innovation funding and savings derived 
from this molecular diagnostic should therefore come 
from the same budget.
 Pursuing Market Access for Molecular Diagnostic 
 Introduction of a new molecular test on the market can 
only occur once it meets all regulatory requirements and 
it receives reimbursement approval within the healthcare 
system. Currently, there are a variety of pathways for in-
troduction which depend on the following parameters: 
(a) the country in which the test is being introduced, (b) 
whether the molecular test is associated with a therapeu-
tic (CDx), (c) whether it is an in vitro diagnostic test or 
an imaging biomarker, (d) whether the test is performed 
locally or in a central lab, and (e) which laboratory disci-
pline performs the test. Each of these factors can influence 
the evidence and regulatory requirements and which 
agencies will evaluate the technology.
 EU Regulatory Framework 
 The regulatory system of the EU provides two broad 
frameworks for approving personalised medicine tech-
nologies: one pathway for medical devices and another 
for in vitro diagnostic devices. Non-in-vitro devices, 
such as imaging devices, used for cancer screening come 
under the Regulation on Medical Devices and Amending 
Directive 2001/83/EC, Regulation (EC) No. 178/2002 
and Regulation (EC), whereas most molecular tests (in-
cluding those classified as CDx) are (and will be) gov-
erned by the framework for in vitro diagnostics (IVDs), 
which encompasses diagnostic products such as reagents, 
instruments and systems intended for use in diagnosis of 
disease.
 Today’s system for IVDs is built largely on a self-cer-
tification procedure, placing heavy responsibility on 
manufacturers. Examples of current obligations include 
having in place a qualitative manufacturing process, user 
instructions that are clear and fit for purpose, ensuring 
that the ‘physical’ features of devices and diagnostics do 
not pose any danger such as electric shocks. If a product 
fulfils these and other related control requirements, it 
may be CE-marked as an indication that the product is 
compliant with EU legislation. The higher the risk associ-
ated with the use of a product, the stricter the obligation 
to perform clinical studies and to involve a so-called No-
tified Body to assess manufacturer compliance with the 
requirements  [39] .
 The existing framework, which dates back to the 1990s, 
is currently under revision. If implemented, the EU Com-
mission’s recent proposal for a regulation on in vitro di-
agnostic medical devices (Proposal for a Regulation on
in vitro Diagnostic Medical Devices) will change the way 
CDxs are regulated. With CDxs becoming one of the 
most important tools in achieving the goals of person-
alised medicine, it is an obvious shortcoming that they are 
not formally acknowledged within the current frame-
work. Without a special distinction, they have to fulfil 
only minimal technical performance requirements and 
qualify for self-certification. This does not adequately 
recognise the impact a CDx has on a patient receiving the 
right treatment (or in avoiding the wrong treatment) 
 [39] .
 The proposed IVD regulation addresses this gap. It 
provides a definition for CDx: ‘a device specifically in-
tended to select patients with a previously diagnosed con-
dition or predisposition as eligible for a targeted therapy’. 
It also classifies IVDs into four risk categories. Based on 
high patient risk, coupled with a moderate public health 
risk, CDx will usually fall into class C – the second-high-
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est risk class and requiring in-depth involvement of a no-
tified body  [15] . Both the specific identification and the 
change in classification are a step in the right direction. 
More rigorous review will help ensure the quality of 
CDxs, protect public health and promote the economic 
benefits of personalised medicine to the healthcare sys-
tem. However, the definition should be improved to en-
sure that this unique class of IVDs, which plays an essen-
tial role in guiding treatment decisions with specific phar-
maceuticals, is subject to a sufficiently high standard to 
guarantee patient safety  [39] .
 Regarding the clinical evidence requirements, the pro-
posal extends and clarifies the rules for clinical evidence 
(‘the information that supports the scientific validity and 
performance for the use of a device as intended by the 
manufacturer’) that IVDs have to follow, with require-
ments proportionate to the risk class. This is a welcome 
step to ensure that diagnostics undergo an adequate vali-
dation process. At the same time, the hurdles should not 
be so high as to make it nearly impossible to introduce a 
diagnostic tool. Diagnostics are different to pharmaceu-
ticals, with shorter life cycles and a very different risk-
benefit profile, explained by the fact that they do not
interact directly with the patient’s body; this means that 
they may merit different standards of clinical evidence in 
order to balance the risk-benefit profile and innovation. 
For instance, in the case of a new CDx, the report of the 
pivotal drug study should suffice to demonstrate both 
clinical performance (‘the association of an analyte to a 
clinical condition or a physiological state’) and scientific 
validity (‘the ability of a device to yield results that are 
correlated with a particular clinical condition or a physi-
ological state in accordance with the target population 
and intended user’ [see  42 ]), without need for further sci-
entific evidence  [39] .
 Depending on the study design, scientific validity 
could be further augmented with information generated 
in earlier-phase drug studies or exploratory research. It 
should also be stated that such joint clinical trials of phar-
maceutical and diagnostic are one, but not the only means 
of achieving the overall objective of clinical evidence.
 For example, for follow-on diagnostics, where other 
manufacturers prepare a new IVD for an analyte that was 
previously included in an assessed and CE-marked CDx, 
a sufficiently robust clinical evidence report should still 
be required. Clinical evidence, however, might be appro-
priately demonstrated by means other than a full pivotal 
drug study, such as a retrospective analysis of clinically 
annotated archival samples  [39] .
 Imaging Biomarkers  
 Going beyond the specific example of CDxs – and, in 
fact, beyond the scope of the IVD regulation – the case of 
imaging biomarkers may further serve to demonstrate the 
relevance of a regulatory framework which guarantees ap-
propriate validation of medical devices and diagnostics. 
Medical imaging plays an important role in the era of per-
sonalised medicine, in particular in the areas of disease pre-
vention, diagnosis, therapy, drug discovery, theranostics, 
image-guided interventions and drug delivery. Medical im-
aging has always been personalised, providing an individu-
al phenotyping with the assessment of the location and se-
verity of an abnormality. In the future, it will play an even 
more fundamental role in personalised medicine and 
should thus be considered an integral part of the entire 
‘-omics’ area. Using imaging biomarkers to streamline 
drug, tumour and disease progression discovery represents 
a clear advancement in healthcare. In order to allow an ef-
fective use of imaging biomarkers, adequate validation and 
standardisation procedures need to be in place. The quali-
fication and technical validation of imaging biomarkers 
poses unique challenges in that the accuracy, methods, 
standardisations and reproducibility are strictly monitored. 
Moreover, there is a strong need to ensure full interopera-
bility among the ‘-omics’ biobanks, imaging databases and 
clinical data stored in electronic medical records  [39] .
 Flexible Regulatory Process to Consider Different 
Diagnostic Models 
 The development and validation of new biomarkers is a 
priority in terms of improving patient management, assess-
ing risk factors and disease prognosis. However, biomark-
ers that do not fit into a standard IVD model face regula-
tory challenges as many country laws restrict who can per-
form diagnostic tests and where they can be performed. 
These laws should evolve to focus more on the evidence 
supporting the use of the test and the quality of the testing 
methods. For example, most imaging biomarkers are not 
covered by the CE mark and do not currently fall under the 
EMA drug approval regulation. They are therefore unlike-
ly to be covered by the EC directive on in vitro devices cur-
rently under development. In order to ensure their effective 
introduction of high-quality biomarkers, structured valida-
tion processes and evidence requirements need to be de-
fined by EU and member state regulatory bodies  [39] .
 Clinical Implementation and Reimbursement 
Pathways 
 Similarly to cancer drugs, recognising the clinical util-
ity of value-based molecular diagnostics and the defini-
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tion of the mechanism of reimbursement are required for 
an effective clinical implementation. This process re-
quires usually two steps. First, there is a health technol-
ogy assessment (HTA) by a regional or national agency, 
which evaluates the clinical utility of the molecular diag-
nostic; if the judgment is positive, a reimbursement rec-
ommendation is given. However, following this step, a 
commissioning decision is required which allows fund-
ing and payment of the molecular diagnostic. Currently, 
a number of European HTA bodies are developing dedi-
cated pathways to assess molecular diagnostics. The Na-
tional Institute for Health and Care Excellence (NICE) in 
the UK was one of the first agencies to set up a dedicated 
assessment pathway for diagnostics in 2009/2010  [40] . 
The aims of the NICE Diagnostics Assessment Pro-
gramme (DAP) are to:
 • Promote the rapid and consistent adoption of clini-
cally innovative and cost-effective diagnostic technol-
ogies across the National Health Service (NHS) 
 • Improve treatment choice or the length and quality of 
life by evaluating diagnostic technologies that have the 
potential to improve key clinical decisions  
 • Promote the efficient use of NHS resources by evaluat-
ing diagnostic technologies that have the potential to 
improve systems and processes for the delivery of 
health and social care 
 This programme was unique in that it developed a spe-
cific methodology to assess diagnostic technologies, while 
other agencies have tried to assess diagnostics as part of 
their current framework. NICE evaluates diagnostic tech-
nologies based on 3 main categories: diagnostic test ac-
curacy, clinical effectiveness and cost-effectiveness  [41] . 
These categories align well with the areas of evidence that 
we have highlighted in this article for molecular diagnos-
tics, which include analytical validation, clinical valida-
tion, clinical utility and cost-effectiveness  [17, 39] .
 While NICE successfully established an assessment 
process for diagnostics, this process still has important 
limitations as diagnostic guidance is not legally binding 
in contrast to therapeutics and does not always specify a 
commissioning route. In other words, there is no obliga-
tion for the NHS to implement the NICE diagnostic guid-
ance, and it is not always clear which budget stream will 
be utilised after NICE publishes its guidance.
 Smaller countries such as Ireland, Switzerland and 
Belgium adopt a more pragmatic approach. Without cre-
ating specific assessment processes, they adapt their exist-
ing pathways to the requirements of molecular diagnos-
tics and rely more on the advice from their clinical experts 
to inform their assessments. Assessing biomarkers re-
mains challenging for healthcare systems especially as the 
field is evolving and there is still uncertainty, especially 
around topics such as tumour heterogeneity, so these 
agencies need to base their decisions on the quality and 
quantity of evidence. Also, in many even after a positive 
health technology assessment, there are funding issues 
such as commissioning options and budget silos  [39] .
 Therefore, new market access and validation models 
should be considered for healthcare systems which sup-
port reimbursement for molecular diagnostics  [21] . After 
the molecular diagnostic is available as part of the health-
care system, molecular diagnostic developers should be 
expected to provide additional evidence on the clinical 
utility of the biomarker in different subgroups of patients. 
Implementing this type of market access scheme would 
greatly enhance the number of biomarkers being intro-
duced, while also better defining in which clinical settings 
these tests have the most value to patients, physicians and 
the healthcare system. This approach, called ‘conditional 
reimbursement’, allows quicker access to validated mo-
lecular diagnostics in a controlled setting, allowing health 
authorities to assess the value and budget impact for the 
healthcare system before committing to broad access 
 [39] .
 The Value-Based Pricing Approach 
 In most healthcare systems today, diagnostics are as-
signed a code and/or a price which is set based on the 
work required to perform the test, not based on the clini-
cal value that the test provides to the healthcare system. If 
drugs were priced this way, pharmaceutical companies 
would only be reimbursed for the manufacturing costs of 
a product without taking into account the huge invest-
ment in research and development, and this approach 
would completely limit any innovation in the field. Simi-
larly, a cost-based pricing approach for diagnostics dis-
incentivises biomarker developers from pursuing evi-
dence which demonstrates clinical value and limits their 
willingness to invest in further research  [13] . An EU 
Commission Staff working document  Use of ‘-omics’ 
Technologies in the Development of Personalised Medi-
cine, published in October 2013, highlighted this point: 
‘the current paradigm where the highest “value” is attrib-
uted to therapies rather than to diagnostics may need to 
be revisited to ensure that high-quality diagnostics are 
also valued appropriately. Such a shift would be expected 
to speed up innovation in the area of personalised medi-
cine’  [42] . Therefore, there is a need to shift the pricing of 
molecular diagnostics to a more value-based approach 
that rewards molecular diagnostic developers for (a) 
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demonstrating the value of their tests to healthcare sys-
tems and (b) sponsoring more research to be conducted 
 [39] .
 Future Considerations 
 Based on rapid advances in sequencing and imaging 
technologies, a wide range of biomarkers are being devel-
oped and studied. Often, new biomarker models are be-
ing proposed that evaluate tumour, serum plasma or 
urine in a dynamic way along different steps of the pa-
tient’s journey. Some of these new approaches require 
new evaluation methodologies to ensure that these mark-
ers are safe and effective in improving patient care. In 
some cases, alternative end points for studies will need to 
be considered to more efficiently introduce biomarkers 
into clinical practice. However, these options can only be 
considered once all known sources of bias are identified 
and appropriate controls established and caveats high-
lighted  [39] .
 As cancer genomics sequencing becomes more wide-
spread, it will be important to understand which onco-
genic drivers may be actionable with different therapeu-
tics and what evidence supports each target and its associ-
ated therapy  [39] .
 Conclusions 
 One of the major barriers limiting the introduction 
personalised cancer medicine is that there is a limited 
number of biomarkers developed and in clinical use to-
day. Technologies like next-generation sequencing have 
great potential to enable better targeting of cancer drugs 
to those patients most likely to benefit. Currently, there 
are many large research initiatives to better characterise 
the underlying biology of cancer (The Cancer Genome 
Atlas, International Cancer Genome Consortium, etc.) 
which will lead to new discoveries and innovations in the 
development of biomarkers. While the field is still in its 
infancy and expected to become more complex, it is im-
portant that policy makers define clear frameworks for 
evaluation of biomarkers which are needed for regulatory 
approval and introduction into healthcare systems. By
establishing clear pathways and evidence requirements, 
biomarker developers can better focus their research to 
meet these objectives.
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